Cannabidiol is a negative allosteric modulator of the cannabinoid CB₁ receptor

Abstract

BACKGROUND AND PURPOSECannabidiol has been reported to act as an antagonist at cannabinoid CB 1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB 1 receptors. EXPERIMENTAL APPROACHInternalization of CB 1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB 1 receptors and in the STHdh Q7/Q7 cell model of striatal neurons endogenously expressing CB 1 receptors. Cells were treated with 2-arachidonylglycerol or Δ 9 -tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. KEY RESULTSCannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ 9 -tetrahydrocannabinol on PLCβ3-and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh Q7/Q7 ) expressing CB 1 receptors. By reducing arrestin2 recruitment to CB 1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB 1 receptor. CONCLUSIONS AND IMPLICATIONSCannabidiol behaved as a non-competitive negative allosteric modulator of CB 1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB 1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB 1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.

Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats

“…37 Understanding the mechanism by which CBD partially ameliorates THC's effects may provide insight into why this effect is not as robust as expected. Recent in vitro evidence suggests that CBD may inhibit the effects of THC through negative allosteric modulation of the CB 1 receptor, 38 whereas human neuroimaging studies indicate that THC and CBD differentially influence brain activity while performing cognitive or emotional tasks. [39][40][41] And while both additive 36 and antagonistic 18,42 associations have been reported between these agents in rodents, to date no studies have provided a direct mechanism as to how CBD moderates THC's behavioural effects.…”

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

“…Mouse vas deferens experiments showed that CBD produces weak antagonism of CB1 receptor agonists (IC 50 ϭ 3.35 M) (680). A recent study, yet to be confirmed by further investigations, points to CBD as a negative allosteric modulator of CB1 (454).…”

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

“…In addition, CBD is a very potent anti-oxidant, more protective than α-tocopherol or vitamin C [16]. On CB1 receptors, CBD acts as negative allosterical modulator, decreasing partially the activity of ligands [17]. On CB2 receptors, CBD can act as receptor-inverse agonist.…”